Antihypertensive utility of perindopril in a large, general practice-based clinical trial.

Stevo Julius, Jay N. Cohn, Joel Neutel, Michael Weber, Prasad Turlapaty, Yannan Shen, Victor Dong, Alicia Batchelor, Hjalmar Lagast

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalJournal of clinical hypertension (Greenwich, Conn.)
Issue number1
StatePublished - Jan 2004


Dive into the research topics of 'Antihypertensive utility of perindopril in a large, general practice-based clinical trial.'. Together they form a unique fingerprint.

Cite this